VEGF-Stimulating Compound for Age-Related Symptom Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aging-related symptoms and diseases, such as whole body weight loss, kyphosis, pancreatic steatosis, and hepatosteatosis, are significant challenges as individuals age, with existing treatments being inadequate.
Innovation Solution
A pharmaceutical composition comprising a vascular endothelial growth factor (VEGF)-stimulating compound, specifically a nucleic acid encoding VEGF-A, is administered to increase plasma VEGF levels by up to three-fold, maintaining this elevation for at least 30 days to treat age-related symptoms and diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If VEGF levels are elevated to treat age-related symptoms, then muscle wasting and steatosis are reduced, but potential harmful effects of VEGF overexpression must be controlled
Solution Approach 1:
The patent applies parameter changes by carefully controlling the magnitude and duration of VEGF elevation. Specifically, VEGF levels are increased by up to three-fold compared to baseline, and this elevation is maintained for at least 30 days. This controlled parameter adjustment allows therapeutic benefits to be achieved while preventing excessive or harmful VEGF overexpression, resolving the contradiction between effectiveness and safety.
2Reliability
If VEGF-stimulating compound is administered to increase plasma VEGF levels, then age-related weight loss and bone fragility are reduced, but the complexity of pharmaceutical composition and administration increases
Solution Approach 1:
The patent specifies precise parameter ranges for the VEGF-stimulating compound administration: plasma VEGF levels are increased by up to three-fold, and this level is maintained for at least 30 days. By defining these specific parameters, the patent simplifies the pharmaceutical composition design and administration protocol, making the treatment approach more manageable despite the biological complexity of VEGF modulation.
3Reliability
If VEGF levels are maintained elevated for at least 30 days, then therapeutic effect is sustained, but the duration of treatment increases
Solution Approach 1:
The patent establishes a minimum treatment duration parameter of 30 days for maintaining elevated VEGF levels. This parameter setting ensures that sufficient time is allowed for therapeutic effects to manifest and be sustained, particularly for conditions like muscle wasting and steatosis that require prolonged treatment. The 30-day minimum provides a balanced approach between achieving sustained therapeutic effect and limiting treatment duration.
Data Source
Figure 1~2B
Figure 3A~3C
Figure 4A~4D
AI summary
The present invention is directed to methods and compositions for treating or attenuating age-related symptoms or diseases in a cell, a tissue, an organ, or an organism by administration of therapeutically effective amounts of VEGF stimulating-, VEGFR stimulating- compound, or any combination thereof.